Dr. Peter Berger, senior vice president for clinical research with the North Shore-LIJ Health System, assessed data from a large clinical trial and said Angiomax, a drug that is 400 times more expensive than old-fashioned heparin, may not be worth the cost during placement of a stent to open a clogged artery. Photo Credit: NSLIJ Dr. Peter Berger, senior vice president for clinical research with the North Shore-LIJ Health System, assessed data from a large clinical trial and said Angiomax, a drug that is 400 times more expensive than old-fashioned heparin, may not be worth the cost during placement of a stent to open a clogged artery.